Skip to main content
BMC Pharmacology & Toxicology logoLink to BMC Pharmacology & Toxicology
. 2021 Apr 29;22:23. doi: 10.1186/s40360-021-00491-0

Transcriptome investigation of anti‐inflammation and immuno‐regulation mechanism of taurochenodeoxycholic acid

Lige Bao 1,2, Dacheng Hao 1,2, Xu Wang 1,2, Xiuling He 1,2, Wei Mao 1,2, Peifeng Li 1,2,
PMCID: PMC8086280  PMID: 33926569

Abstract

Background

Taurochenodeoxycholic acid (TCDCA) is one of the major active components in bile acid. It was proven to have inhibitory activities on inflammation and also participate in host immuno-regulation. TCDCA exerts anti-inflammatory and immuno-regulatory effects through the glucocorticoid receptor (GR) mediated genomic signaling pathway and the G protein-coupled bile acid receptor 5 (TGR5) mediated AC-cAMP-PKA signaling pathway. However, it is unclear whether GR or TGR5 plays an important role in the regulatory effects of TCDCA. In order to further investigate this effects mechanism of TCDCA, the research use the transcriptome to identify the major genes and pathway in the anti-inflammatory and immuno-regulatory effects.

Methods

After the Fibroblast-like synoviocytes (FLS) being treated by different concentrations (10− 5, 10− 6 and 10− 7 M) of TCDCA for 12 h, the resulting mRNA was analyzed by RNA-seq. The differentially expressed genes were screened from sequencing results using bioinformatics techniques. In the next step, other published literature were referred in order to find out whether those genes mentioned above are related to inflammation. The final selected differentially expressed genes associated with inflammation were then validated by q-PCR and western blot assays.

Results

Five genes associated with anti-inflammatory and immuno-regulatory effects, include Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Glutathione peroxidase 3 (GPX3), Serine/arginine-rich splicing factor-9 (SRSF9), Connective tissue growth factor (CTGF) and Cystatin B (CSTB) were identified. TCDCA at the concentrations of 10− 5, 10− 6 and 10− 7 M significantly (p < 0.05) up-regulate the mRNA and protein expression of SRSF9 and GPX3 and also up-regulate the mRNA expression of CSTB, CTGF and GAPDH. RNA-seq results of GPX3 and SRSF9 expression were consistent with q-PCR results, while q-PCR results of CTGF, GAPDH showed inconsistent with their RNA-seq results. Q-PCR result of CSTB expression also showed inconsistent with the RNA-seq result.

Conclusions

The anti-inflammatory and immuno-regulatory activities of TCDCA are proven to be related to the up-regulation expression of GPX3, SRSF9 and CSTB.

Keywords: Taurochenodeoxycholic acid, RNA sequencing, Fibroblast‐like synoviocytes, Glucocorticoid receptor, Serine/arginine-rich splicing factor-9

Background

Taurochenodeoxycholic acid (TCDCA) is one of the main active constituents of bile acids (BAs) [1], which is mainly found in bile from chickens, ducks, cattle, sheep, snakes, bear, and other species [2]. The IUPAC name is 3α,7α-dihydroxy-5β-24-cholanoyl-N-Taurine [1]. TCDCA is synthesized from taurine and chenodeoxycholic acid in the organisms (Fig. 1).

Fig. 1.

Fig. 1

Chemical structure of TCDCA. Molecular weight: 499.69 Da, molecular formula: C23(OH)2H37CONHCH2CH2SO3H

Our pervious research showed that TCDCA had inhibitory effects on both acute and chronic inflammation, and could also regulate immune response [3, 4]. TCDCA reduces capillary permeability and had anti-inflammatory activity against xylene induced mice earlobe edema [5]. It also inhibits toe swelling in complete Freund’s adjuvant (CFA) induced adjuvant arthritis in rats [5]. Studies have shown that TCDCA degrades the level of Leukotriene B4 (LTB4) in peripheral blood. The anti-inflammatory action of TCDCA attributed to down regulation of the expression of LTB4, NO and PEG2 gene. In addition, it inhibits the expression of TNF-α, IL-1β and IL-6 on both mRNA and protein level in synovial tissue and plasma of adjuvant arthritis (AA) rats [3, 6].

The immuno-regulatory activity of TCDCA had been reported, it increases the hemolysin, lysozyme and IgG levels in mouse serum, intensifies phagocytic function of mononuclear-peritoneal macrophages, enhances the percentage of CD3+, CD4+, and CD19+ cells and CD4+/CD8+ ratio in the peripheral blood of mice, and reduce the secretion of IL-1β in peritoneal macrophages [7, 8]. Additionally, TCDCA had regulatory effect on mitogen-stimulated mouse spleen lymphocyte immune function [9].

Other published studies demonstrated that TCDCA exerts anti-inflammatory and immuno-regulatory effects, affects the glucocorticoid receptor (GR) mediated genomic signaling pathway [1012], as well as the G protein-coupled bile acid receptor 5 (TGR5) mediated AC-cAMP-PKA signaling pathway [13, 14]. However, comparison of the regulatory effects of TCDCA on GR and TGR5 had not yet been published, therefore, the objective of our study was to identify the major signaling pathway during the anti-inflammatory and immuno-regulatory effects of TCDCA using Fibroblast-like synoviocytes (FLS) recovered from AA rats’ model.

The development of molecular biology technologies has provided us a new technology termed RNA Sequencing (RNA-seq) for both mapping and quantifying transcriptome [15]. In order to further investigate the mechanism of anti-inflammatory and immuno-regulatory effects of TCDCA, and analyze the major genes and pathways involved, the transcriptional effects of TCDCA on FLS of AA rats was evaluated. Using RNA-seq could get new pathways, transcripts and key differentially expressed genes which come into effect in the process of anti-inflammation and immuno-regulation.

Methods

Adjuvant arthritis induction and cell culture preparation

The animal experiments were approved by the Animal Ethics Committee of Veterinary Medicine College, Inner Mongolia Agricultural University, Hohhot, China and conformed to national guidelines on the care and use of laboratory animals. Male Sprague Dawley (SD) rats (body weight = 100 ± 20 g), were obtained from Experimental Animal Center, Laboratory Animal Research Center, Inner Mongolia Medical University in China. All rats were housed in sawdust-lined cages at constant temperatures (22–25 ℃) and suitable humidity (40–70 %). Food and water were available ad libitum.

After one-week acclimation, AA rat model was established by injecting 0.1 mL CFA to 15 test animals in left hind paw pad intradermally. The mean body weight was recorded, and the day of model establishment was denoted as Day 0 [16]. Animals were fed with standard rodent chow, ad libitum for 13 to 15 days before euthanizing, by cervical dislocation following an inhalation anesthesia with isoflurane: 5 % for induction, 1–3 % for maintenance. Then, fresh synovial tissues were harvested. The tissue samples were washed three times with Dulbecco’s Phosphate Buffered Saline (DPBS), and cut into 1 ~ 2 mm2 tissue fragments then transferred to a culture flask. All flasks were placed inverted and incubated at 37 °C, in 5 % CO2 atmosphere for 2 h. Afterwards, fresh DMEM medium with 20 % fetal bovine serum was added, and incubated at 37 °C, in 5 % CO2 atmosphere for another 7 days. Synovial pieces were removed after the incubation; adherent cells were continuously cultured three generation in the same medium. After the confluence reached approximately 70 ~ 80 %, non-adherent cells were washed off with DPBS and adherent cells were harvested. The third-passage FLS in exponential growth phase were used for further experiments. After three passages, most cells comprise a homogeneous population of FLS [17].

Total RNA extraction and study design

Fibroblast-like synoviocytes (FLS) were treated with TCDCA in different concentrations (10− 5, 10− 6 and 10− 7 M), while control FLS were incubated with DMEM alone (Table 1). All treated cells were incubated at 37 °C, in 5 % CO2 atmosphere for 12 h. Total RNA was extracted using Trizol reagent, quantity and integrity were assessed by 2100 Bioanalyzer (Agilent, USA). The RNA quality evaluation requests that the minimum amount of extracted RNA is 2 µg (concentration of ≥ 50 ng/µL). RIN (RNA integrity number) value for each test groups is required to be greater than 6.4. However, the value of 28 S/18S, whose ratio is a reasonable way to estimate RNA integrity, should be greater than 0.7 [18, 19].

Table 1.

The treatment groups

Group Treatment
TCDCA concentration (M)
AA rat FLS group (FCA group) -
AA rat FLS + TCDCA high dose treatment (AT10 group) 1 × 10− 5
AA rat FLS + TCDCA medium dose treatment (AT1 group) 1 × 10− 6
AA rat FLS + TCDCA low dose treatment (AT01 group) 1 × 10− 7

AA Adjuvant arthritis, FLS Fibroblast-like synoviocytes, TCDCA Taurochenodeoxycholic acid

Transcriptome sequencing and cDNA library construction

Poly A containing mRNA was isolated from approximately 10 µg of total RNA using Poly-T oligo magnetic beads through hybridization, it was then purified and fragmented into small pieces using divalent cations under elevated temperature. The cleaved RNA fragments were reverse-transcribed to cDNAs and constructed the final cDNA library using the mRNA-Seq sample preparation kit protocol. The average insert size for the final cDNA library was 300 bp (± 50 bp). Then the paired-end sequencing was performed using Illumina Hiseq4000 (Illumina, USA).

Sequencing data quality assessment and bioinformatics analysis

Using the Illumina paired-end RNA-seq method, the whole transcriptome was sequenced and generated a total of million paired-end reads of bp length. Before the re-assembly, the low-quality reads were removed. Reads from tested rat samples were aligned to the reference genome using HISAT2 (version 2.0.4), a portion of reads based on quality information were mapped to reference genome [20]. After the final transcriptome was generated, StringTie (version 1.2.4) and Ballgown (version 2.6.0) were used to estimate the expression levels of all transcripts. StringTie was used to evaluated the expression level for mRNAs by calculating Fragments Per Kilobase of exon model per Million mapped reads (FPKM) [21, 22]. The differentially expressed mRNAs and genes were analyzed [log2 (fold change) > 1, log2 (fold change) < -1; statistical significance (p < 0.05)] using Ballgown R package.

The raw data were processed, before obtaining any valid data. The ratio of bases with a mass value of ≥ 20 (Q20 %) and Q30 % are required exceed 90 %. At the same time, the ratio of GC content, was checked to determine whether there is a separation between AT and CG. The repeatability of each sample was determined based on the results of Principal Components Analysis (PCA) 3D map and the correlation analysis map. Expression level and differential expression level between different genes were further investigated if the result of repeatability was high. The differentially expressed genes in each sample group were evaluated by FPKM, P value (Probability value), gene with FPKM value greater than 100 or have major changing in FPKM value were chosen to be used as verification targets for further analysis [23]. Other function analyses used include GO (Gene Ontology) enrichment analysis and KEGG (Kyoto Encyclopedia of Genes and Genomes) signal pathway enrichment analysis, to select differentially expressed genes which were related to anti-inflammatory and immuno-regulatory effects.

After selecting the differentially expressed genes, Gene ID and/or the Transcript ID of those genes were searched in the protein annotation database (provided by LC Sciences). Name of the protein and its gene were determined based on the searching results, genes relating to anti-inflammation and immuno-regulation were identified based on others published literature.

The RNA-seq profiles by quantitative real‐time PCR (q-PCR) assays

Differentially expressed genes related to anti-inflammatory and immuno-regulatory effects were selected for further validation by q-PCR analysis. Total RNA was extracted using the same batch of FLS as RNA-seq. The mRNA expression levels of five differentially expressed genes in both control and TCDCA (10− 5, 10− 6, 10− 7 M) treated groups were validated. The total mRNA was extracted from FLS in 6-well plates by AxyPrep Total RNA Extraction Kit. The ratio of OD260/280 and agarose gel electrophoresis were determined to ensure the quality of RNA [16]. Synthesis of cDNA was carried out using q-PCR (Hiscript® Q RT SuperMix) following the manufacturer’s protocol. Total cDNA was used as starting material for quantitative real-time PCR [FastStart Universal SYBR Green Master equipped with Q7 system (ABI Biosystemss, USA)]. Q-PCR reaction system need total 20 µL of reaction mixture including 2 µL of cDNA, 10 µL of SYBR, 0.8 µL of specific target primers (10 µM)forward and reverse and 6.4 µL of double distilled H2O [17]. The q-PCR analysis was carried out using specific primers (Table 2). All data were calculated based on the comparative Ct formula and each sample was normalized by β-actin [24]. Relative mRNA expressions were analyzed according to the Ct values, based on the equation: 2−ΔCt [ΔCt = Ct (SRSF9/GPX3/CSTB/CTGF/GAPDH) - Ct(β-actin)].

Table 2.

Primers sequence

Gene name Sequence (5′ → 3′)
SRSF9 Forward: ATTTGGTGTCATCCAGTTTCC
Reverse: CAGATTTCCGAGTTCTTGTTTC
GPX3 Forward: GGTGTTGTACCAAACCGTGAG
Reverse: ATCCCAGATTCCCTTCCTTAT
CSTB Forward: GGAAAGAAACAAAATACAACG
Reverse: TACCAGACCGACAAAGAAAAG
CTGF Forward: AGTTCGTGTCCCTTACTCCCT
Reverse: AAGACCTGTGCCTGCCATTAC
GAPDH Forward: TCACCCCATTTGATGTTAGCG
Reverse: GCAAGTTCAACGGCACAGTCA
β-actin Forward: GGAGATTACTGCCCTGGCTCCTA
Reverse: GACTCATCGTACTCCTGCTTGCTG

Total protein extraction

FLS cells from the same batch used for the RNA-seq assay were used for total protein extraction. The protein expression level of differentially expressed genes in both control and TCDCA treated groups were verified. Extraction procedures followed the manufacturer’s protocol using M-PER Mammalian Protein Extraction Reagent kit. After the treatment, medium was removed and 1 mL of M-PER Reagent was added to each flask. All flasks were shaken gently for 5 min, then cells at the bottom of the flasks were scraped off. All cells were suspended in the reagent, vortexed and centrifuged at 14,000 g for 10 min at 4 °C. The supernatant was collected and stored at -80 ℃.

Assessment of relationship between SRSF9 and GPX3 and inflammatory and immuno-regulatory process using western blotting

Protein standard curve was established using the Pierce™ BCA Protein Assay Kit and protein concentration in test samples were determined. For western blotting analysis, 6 µg of total protein per lane was separated by 12 % SDS-PAGE and blotted onto a PVDF membrane. Rabbit anti-mouse SRSF9 (1:500), goat anti-mouse GPX3 polyclonal antibodies (1:167) and β-actin mouse monoclonal antibody (1:3000) were used for protein detection. Proteins were then treated using secondary horseradish peroxidase (HRP)-conjugated rabbit anti-goat (1:3000), goat anti-mouse antibodies (1:3000), goat anti-rabbit antibody (1:3000) and Pierce SuperSignal West Femto chemiluminescent substrate (Thermo Fisher Scientific, USA). The bands were visualized by maximum sensitivity substrate. Chemiluminescence signals were measured using the ECL system (ImageQuantLAS4000, GE Healthcare). Protein signal intensity was measured by densitometric analysis using ImageJ software (version 1.48).

Statistical analysis

All data were analyzed using SPSS 19.0 software, and presented as mean ± standard deviation (SD). T-test was used for two groups comparison, while one-way ANOVA was used when more than two groups were compared. P < 0.05 (represented as *), p < 0.01 (represented as **) and p < 0.001 (represented as ***) were considered as significant.

Results

The FLS cells

FLS cell (Fig. 2a) was spindle shaped and had protruding protrusions. During the cell culture, when the confluence reached 50 ~ 60 %, it could be sub-cultured and the morphology of third generation cells were recorded (Fig. 2b). After the sub-culturing, cell changed into elongated shape, and dedifferentiate into fibroblast-like cells.

Fig. 2.

Fig. 2

Fibroblast-like synoviocytes condition by light microscopy (200×)

Quality of total RNA and transcriptome sequencing quality control

The RNA quality shown that single signal peak of both 18 and 28 S were detected, which indicated the extracted RNA was purified and qualified, RIN values of all groups were greater than 6.4, and 28 S/18S > 0.7. Total extracted amount of RNA was beyond 2 µg, and concentration was measured up to 50 ng/µL, all parameters indicated the extracted RNA was qualified for transcriptome sequencing.

Results from the comprehensive evaluations of the transcriptome sequencing quality are presented in Table 3. Data from 8 out of 12 samples were higher than 7G, while Q20 % and Q30 % of all samples were all higher than 90 %, and the proportion of GC content were all close to 50 % (Table 3). Results of repeatability analysis among samples were displayed in three-dimensional image of PCA (Fig. 3a), the distribution of sample peaks (10 out of 12) were close to each other. While correlation cluster diagram illustrated that sample correlation between each other was high and close to 1 (Fig. 3b).

Table 3.

RNA-seq data quality analysis results

Sample name Raw data Valid data Efficient(reads)% Q20 % Q30 % GC content%
Read Base Read Base
FCA1 54,383,990 8.16G 53,835,634 8.08G 98.99 99.58 95.01 51.50
FCA2 41,050,214 6.16G 40,649,424 6.10G 99.02 99.77 96.14 52.00
FCA3 40,700,236 6.11G 40,326,736 6.05G 99.08 99.76 95.82 51.50
AT10_1 40,741,106 6.11G 40,307,186 6.05G 98.93 99.60 95.16 51.00
AT10_2 57,742,958 8.66G 57,142,398 8.57G 98.96 99.42 92.66 50.50
AT10_3 51,520,986 7.73G 50,998,720 7.65G 98.99 99.62 93.96 50.50
AT1_1 54,593,420 8.19G 54,067,912 8.11G 99.04 99.60 93.56 51.00
AT1_2 46,452,368 6.97G 46,050,198 6.91G 99.13 99.63 93.87 51.50
AT1_3 50,198,580 7.53G 49,764,940 7.46G 99.14 99.32 91.97 51.00
AT01_1 56,340,820 8.45G 55,884,918 8.38G 99.19 99.38 92.94 52.50
AT01_2 52,741,640 7.91G 52,255,040 7.84G 99.08 99.58 94.17 51.50
AT01_3 85,115,910 12.77G 84,203,182 12.63G 98.93 99.58 94.00 50.50

In the experimental design, the AA rat FLS group was represented as FCA groups in the Table 1; AA rat FLS + TCDCA high dose treatment was represented as AT10 group; AA rat FLS + TCDCA medium dose treatment was represented as AT1 group; AA rat FLS + TCDCA low dose treatment was represented as AT01 group; The numbers 1, 2, and 3 represented three sets of repeated studies

Fig. 3.

Fig. 3

Three-dimensional image of PCA (a) and correlation cluster diagram (b)

Differentially expressed genes analysis

Differential analysis of the transcript expression from all samples were profiled. The results demonstrated that 324 genes were significantly altered (≥ 2-fold, p < 0.05), among them, 139 genes were upregulated and 185 genes were downregulated (Figs. 4 and 5). Further investigations on 324 differentially expressed genes were carried out, the specified differentially expressed genes in each sample group was then evaluated by FPKM and P value. Finally, 24 differentially expressed genes were selected between the groups and the results presented in Fig. 6.

Fig. 4.

Fig. 4

Differentially expressed gene regulation results among groups. Red: significantly up-regulated differentially expressed genes; blue: significantly down-regulated differentially expressed genes

Fig. 5.

Fig. 5

Volcano graph of 324 differentially expressed genes among groups. Red: significantly up-regulated differentially expressed genes; blue: significantly down-regulated differentially expressed genes; and gray: non-significantly differentially expressed genes

Fig. 6.

Fig. 6

Differentially expressed genes in each group. P-value has been rounded to two digits

Anti‐inflammation and immuno‐regulation related differentially expressed genes

Five genes were identified to be related to anti-inflammation and immuno-regulation, which were GAPDH, GPX3, SRSF9, CTGF and CSTB (Table 4). Two other anti-inflammation related genes (Slc39a3 and LOC100363502) were also identified by referring to published literature. Slc39a3 (Zinc transporter ZIP3) is associated with anti-inflammatory effects, however, the expression level of it is low and not suitable for further analysis. Gene LOC100363502 and its translation product was identified as Cytochrome C, also known as CYC. It was reported that the increase of expression of CYC may relate to inflammatory activities. Since the subtype of CYC was not clear, no further analysis has been performed in this study.

Table 4.

Anti-inflammatory and immune-regulatory effects related differentially expressed genes and their FPKM

No. Gene ID Gene Name Protein Annotation Group FPKM
Before administration / High dose After administration / Low dose
1 MSTRG.13790 LOC108351137 Glyceraldehyde-3-phosphate dehydrogenase, GAPDH AA VS AT10 1221.52 1284.88 1228.59 0 0 0
AA VS AT01 1221.52 1284.88 1228.59 0 0 0
AT10 VS AT1 0 0 0 1166.15 1257.69 1155.12
AT1 VS AT01 1166.15 1257.69 1155.12 0 0 0
2 MSTRG.2701 GPX3 Glutathione peroxidase 3, GPX3 AA VS AA01 118.24 211.05 129.51 378.47 320.96 304.55
3 MSTRG.4849 SRSF9 Serine/arginine-rich splicing factor-9, SRSF9 AA VS AT1 14.19 15.7 15.56 33.01 35.53 30.19
4 MSTRG.121 CTGF Connective tissue growth factor, CTGF AA VS AT10 703.83 755.68 623.55 190.01 716.87 141.59
5 MSTRG.10440 CSTB Cystatin B, CSTB AA VS AT01 180.14 180.15 185.93 75.93 80.14 190.53
AT1 VS AT01 187.17 187.48 174.88 75.93 80.14 190.53

Research indicated that other unselected differentially expressed genes were not likely to associate with inflammation, and few publications were found. So, only five of the identified differentially expressed genes were selected for further analysis.

Protein and mRNA assessment results of SRSF9 and GPX3

The correlation between gene SRSF9, GPX3 and anti-inflammatory and immuno-regulatory effects were verified by q-PCR and western blot assays. The mRNA level and protein expression levels of these two genes in control and TCDCA (10− 5 M, 10− 6 M, 10− 7 M) treated groups were analyzed. The results showed that mRNA and protein expression level of SRSF9 were significantly increased (Fig. 7) after treatment with TCDCA (10− 5 M, 10− 6 M, 10− 7 M), when compared to the control group (p < 0.05). TCDCA (10− 5 M, 10− 6 M, 10− 7 M) significantly (Fig. 8) enhanced the GPX3 mRNA and protein expression level, when compared with the control group (p < 0.05).

Fig. 7.

Fig. 7

The mRNA (a) and protein (b) expression level of SRSF9. * p < 0.05; *** p < 0.01

Fig. 8.

Fig. 8

The mRNA (a) and protein (b) expression level of GPX3. * p < 0.05; *** p < 0.01

mRNA assessment results of CSTB、CTGF and GAPDH

The mRNA expression levels of three selected genes (CSTB、CTGF and GAPDH) in both control and TCDCA treated groups were analyzed. The results illustrated that mRNA expression level of CSTB were significantly increased after treatment with TCDCA at different concentrations when compared to the mRNA level in control group (p < 0.05, Fig. 9a). While TCDCA (10− 5 M) treatment significantly (p < 0.05) enhance CTGF mRNA expression (Fig. 9b). The results showed that mRNA expression level of GAPDH were significantly increased (p < 0.05, Fig. 9c) after treatment with TCDCA (10− 5 M, 10− 7 M) compared to the control group.

Fig. 9.

Fig. 9

The mRNA expression levels of CSTB, CTGF and GAPDH. * p < 0.05; ** p < 0.01; *** p < 0.01

Discussion

TCDCA is synthesized with taurine and chenodeoxycholic acid in organism, and it is also one of the main bioactive substances of bile from animal bile. It has inhibitory effects on inflammation and could also regulate immune function [1, 3, 4]. The previous studies demonstrated that TCDCA exerts anti-inflammatory and immuno-regulatory effects, in both GR mediated genomic signaling pathway, and TGR5 mediated AC-cAMP-PKA signaling pathway [1014]. In order to further investigate the major genes and pathways involved in the TCDCA relating to anti-inflammatory and immuno-regulatory effects, FLS from AA rats was used in our research, and transcriptome sequencing was used for differential gene investigation.

Differentially expressed genes were analyzed and selected by bioinformatics assays. Twenty-four differentially expressed genes were selected from RNA-seq results, among which five differentially expressed genes were identified by q-PCR. There were five genes relating to anti-inflammatory and immuno-regulatory effects, including SRSF9, GPX3, CTGF, CSTB and GAPDH.

Previous studies confirm that TCDCA can exert effects through GR [12, 25]. Then, the analytical of the SRSF9 showed that the mRNA expression and protein expression of SRSF9 were significantly increased in the treatment groups, this finding also confirmed our transcriptome sequencing results. According to Buoso et al. (2017), the up-regulated GR mRNA was caused by increasing expression of the splicing factor SRSF9 [26]. So TCDCA could increase the expression level of SRSF9 and enhanced the expression of GR as a result.

The results showed that the expression of GPX3 mRNA and protein was significantly increased in the TCDCA treatment groups. According to Manzanares’ finding (2008), patients with systemic inflammatory response syndrome (SIRS) showed significant decrease in the expression of GPX3 [27]. This indicates that GPX3 expression level will be significantly increased when inflammation response was inhibited. Therefore, the anti-inflammatory and immuno-regulatory effects of TCDCA could be related to the increased expression level of SRSF9, and are subsequently related to the increased expressions of GR and GPX3.

According to Maher’s findings (2014), the CSTB-deficient mice were significantly more sensitive to the lethal LPS-induced sepsis and could secrete higher amounts of pro-inflammatory cytokines IL-1β and IL-18 [28]. Q-PCR analytical results indicated that the CSTB mRNA expression levels of the TCDCA treatment groups were significantly increased, which is also consistent with some publications [28]. So, it is also opined that TCDCA can increase the expression level of CSTB.

The q-PCR results of differentially expressed genes CTGF and GAPDH were inconsistent with the transcriptome sequencing results. There was variation with transcriptome sequencing readouts, because Transcriptome sequencing and q-PCR are two different detection methods, and a certain degree of inconsistency (30 ~ 40 %) is both normal and reasonable phenomenon [29]. The final data and conclusions are subject to the q-PCR results. So, the inconsistent results were acceptable.

According to the above discussion, SRSF9 gene could modulate the expression of GR and have potential effect on GR modulated genomic signaling pathway. However, no differentially expressed genes were proven to have modulatory effects on the TGR5 mediated AC-cAMP-PKA signaling pathway. GR plays a critical role in the anti-inflammation and immune regulation after treatment of TCDCA in FLS model.

Conclusions

In this research, five differentially expressed genes GAPDH, GPX3, SRSF9, CTGF and CSTB were selected and identified through the process and was investigated by bioinformatics analysis and assays. It could be concluded that the anti-inflammatory and immuno-regulatory effects of TCDCA is related to the activation of GR and the up-regulation of SRSF9, GPX3 and CSTB. This suggests that GR plays a more critical role in anti-inflammatory and immuno-regulatory effects than TGR5.

Acknowledgements

Not applicable.

Abbreviations

TCDCA

Taurochenodeoxycholic acid

CFA

Complete Freund’s adjuvant

GR

Glucocorticoid receptor

TGR5

G protein-coupled bile acid receptor 5

FLS

Fibroblast-like synoviocytes

AA

Adjuvant arthritis

RNA-seq

RNA sequencing

FPKM

Fragments per kilobase of exon model per million mapped reads

PCA

Principal components analysis

GO

Gene ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

UDCA

Ursodeoxycholic acid

GAPDH

Glyceraldehyde-3-phosphate dehydrogenase

GPX3

Glutathione peroxidase 3

SRSF9

Serine/arginine-rich splicing factor-9

CTGF

Connective tissue growth factor

CSTB

Cystatin B

Authors’ contributions

BLG made majority contribution to the conception of this study, carried out all of experiments, and prepared the first draft of this manuscript. LPF, HXL and MW agreed the final design of this work and revised this manuscript critically. HDC and WX performed cell culture and Western blot. All authors have read and approved the final manuscript.

Funding

This work was supported by National Natural Science Foundation of China (No. 31160518 and No. 31402248). The funding body does not play any roles in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The sequencing data determined in this work have been deposited in the NCBI GEO public database (https://www.ncbi.nlm.nih.gov/gds/) and are accessible through GEO series accession number GSE167513.

Declarations

Ethics approval and consent to participate

The animal experiments were approved by the Animal Ethics Committee of Veterinary Medicine College, Inner Mongolia Agricultural University, Hohhot, China and conformed to national guidelines on the care and use of laboratory animals.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing financial interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.He X, Guan H, Li P. Taurochenodeoxycholic acid research progress. Anim Husbandry Feed Sci. 2008;3:57–60. [Google Scholar]
  • 2.Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal. 2008;20(12):2180–97. doi: 10.1016/j.cellsig.2008.06.014. [DOI] [PubMed] [Google Scholar]
  • 3.Li P, Guan H, Hasi S, Cao J. Anti-inflammatory effect study of chicken bile’s effective components CDCA and the TCDCA. J Tradit Chin Vet Med. 2002;1:7–10. [Google Scholar]
  • 4.Hu X, Shi C. Compare of tauro-conjugated bile acids with the corresponding free bile acids in antiussive, expectorant and anti-inflammatory effects. Chin J Clin Pharm. 2001;2:85–8. [Google Scholar]
  • 5.Liu M, Mao W, Guan H, Li L, Wei B, Li P. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011;11(12):2150–8. doi: 10.1016/j.intimp.2011.09.011. [DOI] [PubMed] [Google Scholar]
  • 6.Shi Y, Li P, Li J, Guan H. Regulation effect of taurochenodeoxycholic acid immune function in mice. Chin Pharmacol Bull. 2007;23(7):859–65. [Google Scholar]
  • 7.He X, Li P, Guan H, Hasi S, Jin S. Effects of taurochenodeoxycholic acid on immune function in mice. J Chin Med Mater. 2005;28(12):1089–92. [PubMed] [Google Scholar]
  • 8.Li P, Liu M, Guan H. Study on effect of taurochenodeoxycholic acid on gene expression of interleukin-2 in the spleen of mouse. China Anim Husbandry Vet Med. 2009;36(03):66–71. [Google Scholar]
  • 9.Liu M, Guan H, Li C, Wei B, Li P. Effects of taurochenodeoxycholic acid on T and B lymphocytes in peripheral blood and spleen of mice. China Anim Husbandry Vet Med. 2009;36(2):50–3. [Google Scholar]
  • 10.Moutsatsou P, Kassi E, Papavassiliou AG. Glucocorticoid receptor signaling in bone cells. Trends Mol Med. 2012;18(6):348–59. doi: 10.1016/j.molmed.2012.04.005. [DOI] [PubMed] [Google Scholar]
  • 11.Chrousos GP, Kino T. Glucocorticoid signaling in the cell. Ann N Y Acad Sci. 2009;1179(1):153–66. doi: 10.1111/j.1749-6632.2009.04988.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Liu HS, Shi HL, Huang F, Peterson KE, Wu H, Lan YY, et al. Astragaloside iv inhibits microglia activation via glucocorticoid receptor mediated signaling pathway. Sci Rep. 2016;6:19137. doi: 10.1038/srep19137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Shi L, Liu Q, Zhang Z, Liu C, Wang X, Deng Y, Li P. Construction of bile acid receptor TGR5 eukaryotic expression vector and its expression in cell. China Anim Husbandry Vet Med. 2014;41(5):17–22. [Google Scholar]
  • 14.Shi L. Studies on interacation of TCDCA and TGR5. Inner Mongolia Agricultural University Master’s Thesis. 2014. p. 9–42.
  • 15.Wang Z, Gerstein M, Snyder M. RNA-seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63. doi: 10.1038/nrg2484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Li L, Liu C, Liu M, Shi L, Liu Q, Guan H, et al. Taurochenodeoxycholic acid induces apoptosis of fibroblast-like synoviocytes. Eur J Pharmacol. 2013;706(1–3):36–40. doi: 10.1016/j.ejphar.2013.02.051. [DOI] [PubMed] [Google Scholar]
  • 17.Wang X, Zhang Z, He X, Mao W, Zhou L, Li P. Taurochenodeoxycholic acid induces nr8383 cells apoptosis via pkc/jnk-dependent pathway. Eur J Pharmacol. 2016;786:109–15. doi: 10.1016/j.ejphar.2016.06.007. [DOI] [PubMed] [Google Scholar]
  • 18.Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbour Laboratory Press; 1989.
  • 19.Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3. doi: 10.1186/1471-2199-7-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357–60. doi: 10.1038/nmeth.3317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Pertea M, et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290–5. doi: 10.1038/nbt.3122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Frazee AC, et al. Ballgown bridges the gap between transcriptome assembly and expression analysis. Nat Biotechnol. 2015;33:243–6. doi: 10.1038/nbt.3172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Niu C, Cheng C, Liu Y, Huang S, Fu Y, Li P. Transcriptome profiling analysis of bovine vaginal epithelial cell response to an isolated lactobacillus strain. mSystems. 2019;4(5):e00268-19. doi: 10.1128/mSystems.00268-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Liu W, Xu G, Ma J, Jia W, Li J, Chen K, et al. Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma. Tohoku J Exp Med. 2011;224:29–39. doi: 10.1620/tjem.224.29. [DOI] [PubMed] [Google Scholar]
  • 25.Li L. Studies on interactions between TCDCA glucocorticoid receptor and its influence on activator protein-1. Inner Mongolia Agricultural University Master’s Thesis. 2014. p. 30–35.
  • 26.Buoso E, Galasso M, Ronfani M, Serafini MM, Lanni C, Corsini E, et al. Role of spliceosome proteins in the regulation of glucocorticoid receptor isoforms by cortisol and dehydroepiandrosterone. Pharmacol Res. 2017;120:180–7. doi: 10.1016/j.phrs.2017.03.019. [DOI] [PubMed] [Google Scholar]
  • 27.Manzanares W, Torre MH, Biestro A, Pittini G, Facchin G, et al. Serum selenium and glutathione peroxidase activity in critically ill patients with systemic inflammatory response and multiple organ dysfunction syndromes. Nutrition. 2008;24(5):506–7. doi: 10.1016/j.nut.2008.01.036. [DOI] [Google Scholar]
  • 28.Maher K, Jeric Kokelj B, Butinar M, Mikhaylov G, Mancek-Keber M, Stoka V, et al. A role for stefin b (cystatin b) in inflammation and endotoxemia. J Biol Chem. 2014;289(46):31736–50. doi: 10.1074/jbc.M114.609396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.SEQC/MAQC-III Consortium. Su Z, Łabaj P, et al. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nat Biotechnol. 2014;32:903–14. doi: 10.1038/nbt.2957. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The sequencing data determined in this work have been deposited in the NCBI GEO public database (https://www.ncbi.nlm.nih.gov/gds/) and are accessible through GEO series accession number GSE167513.


Articles from BMC Pharmacology & Toxicology are provided here courtesy of BMC

RESOURCES